M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal BioPharma DiveThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.Rare DiseaseRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) BioPharma Dive The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients. Rare Disease Read full story Post navigation Previous: AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore projectNext: Decoding Medicare Advantage Coding Intensity Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026